chevron_leftBack
As of 5 June 2026, Algernon Health Inc. has a market cap of $1.75M USD, ranking #47456 globally and #2501 in Canada.
It ranks #4211 in the Healthcare sector, and #824 in the Biotechnology industry.
Key Stats
Market Cap
$1.75MUSD
2.44M CAD
Enterprise Value
$2.34MUSD
3.25M CAD
EBITDA (TTM)
-$1.23MUSD
-1.71M CAD
Net Income (TTM)
-$1.39MUSD
-1.93M CAD
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher Moreau
open_in_new
Founded
2015
Website
algernonhealth.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -92% | -89% | -92% | -94% | -95% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AGN
ISIN: CA01559C1068
Shares Out.:
Shares Outstanding:
46.499M1
Shares Float:
39.494M2
|
0.0450 CAD | |
|
AGN
ISIN: CA01559C1068
|
0.0500 CAD | |
|
AGNPF
Algernon Pharmaceuticals Inc Class A
ISIN: CA01559R4008
Shares Out.:
Shares Outstanding:
34.256M1
Shares Float:
28.663M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0483 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Algernon Health Inc.
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AUPH
|
$1.99B
113K%
|
7.4
|
|
NASDAQ: ABCL
|
$1.16B
66K%
|
-
|
|
TSX: EPRX
|
$432.32M
25K%
600.89M CAD
|
-
|
|
TSXV: NGEN
|
$295.12M
17K%
410.19M CAD
|
-
|
|
NEO: CYBN
|
$254.07M
14K%
353.13M CAD
|
-
|
|
TSX: CRDL
|
$149.71M
8K%
208.08M CAD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
10M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
9M%
|
19.0
|
|
EBR: ARGX
|
$48.01B
3M%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.48B
3M%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$43.01B
2M%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.55B
2M%
33.71B CHF
|
37.2
|
chevron_leftBack